$15.90+0.45 (+2.91%)
Carlsmed Inc. (CARL) is a Medical/Dental Instruments company listed on NASDAQ. In the last 30 days Quantisnow tracked 13 wire items for CARL, including 5 insider trades, 3 SEC filings and 2 leadership changes. The most recent was published Oct 27, 2026.
Price$15.90+3.57 (+28.95%)
2026-07-282026-10-28
News · 26 weeks35-73%
2026-05-032026-10-25
Mix2490d
- Insider8(33%)
- SEC Filings7(29%)
- Other5(21%)
- Earnings2(8%)
- Leadership2(8%)
Latest news
25 items- PRCarlsmed, Inc. to Report Third Quarter 2026 Financial Results on November 10, 2026CARLSBAD, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (NASDAQ:CARL) ("Carlsmed" or the "Company"), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced it will report its third quarter 2026 financial results after market close on Tuesday, November 10, 2026. Management will also host a conference call and concurrent webcast starting at 1:30 PM Pacific Time. A live webcast of the conference call will be available in the Events & Presentations section of the Company’s investor website at investors.carlsmed.com. Participants may also join via telephone by registering here. A replay will be archived on the Company’s website follo
- SECSEC Form 144 filed by Carlsmed Inc.144 - CARLSMED, INC. (0001794546) (Subject)
- PRCarlsmed Launches aprevo® Lumbar Bi-lateral Posterior SystemCARLSBAD, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (NASDAQ:CARL) ("Carlsmed" or the "Company"), today announced the U.S. commercial launch of its aprevo® Lumbar Bi-lateral Posterior System at the North American Spine Society’s 41st Annual Meeting (NASS) in San Antonio, TX. The launch follows a limited market evaluation that commenced in February 2026, with the first in human procedure completed on February 10, 2026. "The launch of the Bi-lateral System further expands our proprietary technology platform to enable a direct posterior approach for personalized spine fusion," said Mike Cordonnier, Chairman and CEO of Carlsmed. "The Bi-lateral System is optimized to support pla
- INSIDERSEC Form 4 filed by Carlsmed Inc.4 - CARLSMED, INC. (0001794546) (Issuer)
- PRCarlsmed, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CARLSBAD, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (NASDAQ:CARL) ("Carlsmed" or the "Company"), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced that on September 28, 2026, it granted stock options to purchase 180,137 shares of the Company’s common stock and 89,286 time-based restricted stock units ("RSUs") to Richard Heppenstall, the Company’s newly-hired Chief Financial Officer, as a material inducement to his employment. The Company further announced that on October 1, 2026, it granted stock options to purchase 132,464 shares of the Company’s common stock and 63,735 time-based RSUs to Anthony Jarc, the Company’s ne
- INSIDERChief Operating Officer Bertolini Jeffrey sold $3,400 worth of shares (243 units at $13.99) as part of a pre-agreed trading plan and exercised 243 shares at a strike of $2.23 (SEC Form 4)4 - CARLSMED, INC. (0001794546) (Issuer)
- SECSEC Form S-8 filed by Carlsmed Inc.S-8 - CARLSMED, INC. (0001794546) (Filer)
- PRCarlsmed Appoints Tony Jarc as Chief Product and AI OfficerCARLSBAD, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (NASDAQ:CARL) ("Carlsmed" or the "Company"), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced that Tony Jarc, Ph.D. has been appointed to the newly-created position of Chief Product and AI Officer, effective immediately. Dr. Jarc will lead the development and commercialization of the Company’s next generation technology platform, surgical UI/UX, and personalized spine surgery procedures. "Tony’s addition comes at a pivotal moment as we transform our technology platform to scale and advance our patient-centric innovation for our highly differentiated personalized surge
- INSIDERNew insider Kamocsay Jennifer claimed ownership of 56,222 shares (SEC Form 3)3 - CARLSMED, INC. (0001794546) (Issuer)
- INSIDERCFO, Treasurer Heppenstall Richard was granted 89,286 shares (SEC Form 4)4 - CARLSMED, INC. (0001794546) (Issuer)
- INSIDERSEC Form 3 filed by new insider Heppenstall Richard3 - CARLSMED, INC. (0001794546) (Issuer)
- SECCarlsmed Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - CARLSMED, INC. (0001794546) (Filer)
- PRCarlsmed Appoints Richard Heppenstall as Chief Financial OfficerCARLSBAD, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (NASDAQ:CARL) ("Carlsmed" or the "Company"), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced that Richard Heppenstall has been appointed Chief Financial Officer, effective immediately. Mr. Heppenstall succeeds Leo Greenstein, who has served as CFO since 2023 and will be leaving Carlsmed to pursue other professional interests. "We are excited to welcome Rich to Carlsmed at a pivotal point for the Company," said Mike Cordonnier, Chairman and CEO. "He is a proven leader with the deep Orthopedic and Tech expertise crucial to driving our strategy, and his deep financial
- PRCarlsmed, Inc. Files Patent Infringement Lawsuit against DeGen MedicalCARLSBAD, Calif., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (NASDAQ:CARL) ("Carlsmed" ), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today filed a patent infringement lawsuit against DeGen Medical, Inc. ("DeGen") in the United States District Court for the District of South Carolina Florence Division. The complaint asserts that DeGen is infringing eight of Carlsmed’s patents relating to its implants, methods and systems. Carlsmed is seeking injunctive relief and damages for infringement. "Carlsmed is dedicated to advancing the standard of care in spine surgery through our proprietary personalized spine surgery solutions and bringing va
- INSIDERAmendment: Large owner Presidio Management Group Xii, L.L.C. bought $3,000,000 worth of shares (200,000 units at $15.00) (SEC Form 4)4/A - CARLSMED, INC. (0001794546) (Issuer)
- INSIDERSEC Form 4 filed by Chief Operating Officer Bertolini Jeffrey4 - CARLSMED, INC. (0001794546) (Issuer)
- INSIDERNew insider Bertolini Jeffrey claimed ownership of 22,489 shares (SEC Form 3)3 - CARLSMED, INC. (0001794546) (Issuer)
- SECCarlsmed Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - CARLSMED, INC. (0001794546) (Filer)
- PRCarlsmed, Inc. Announces Chief Operating Officer AppointmentCARLSBAD, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (NASDAQ:CARL) ("Carlsmed" or the "Company"), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced that Jeff Bertolini has been promoted to the role of Chief Operating Officer, effective immediately. Jeff joined Carlsmed in September 2024, most recently serving as the Company’s Senior Vice President, Operational Excellence and previously, Vice President of Advanced Manufacturing Technologies. Prior to joining Carlsmed, Jeff held senior leadership positions in operations and technology at SI-BONE, NuVasive, and US Surgical. "Jeff has made measurable contributions to our op
- SECSEC Form EFFECT filed by Carlsmed Inc.EFFECT - CARLSMED, INC. (0001794546) (Filer)
- SECSEC Form 10-Q filed by Carlsmed Inc.10-Q - CARLSMED, INC. (0001794546) (Filer)
- SECCarlsmed Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - CARLSMED, INC. (0001794546) (Filer)
- PRCarlsmed® Reports Second Quarter 2026 Financial Results and Raises Full-Year GuidanceSecond quarter 2026 revenue of $18.9 million, representing 57% growth year-over-year Full year 2026 revenue guidance raised to $74 million to $78 million CARLSBAD, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (NASDAQ:CARL) ("Carlsmed" or the "Company"), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today reported financial results for the second quarter ended June 30, 2026. "Our second quarter 2026 results reflect the growing momentum of aprevo® procedures and further progress on our path to profitability," said Mike Cordonnier, Chairman and Chief Executive Officer. "We delivered 57% revenue growth year-over-year, expanded gross mar
- PRCarlsmed Announces Favorable Reimbursement for aprevo® lumbar ProceduresCARLSBAD, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (NASDAQ:CARL) ("Carlsmed" or the "Company"), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced that the Centers for Medicare & Medicaid Services (CMS) has finalized a favorable reimbursement policy applicable to inpatient aprevo® Lumbar spinal fusion procedures in the Hospital Inpatient Prospective Payment System (IPPS) Final Rule for fiscal year 2027 (FY27). The new MS-DRG assignments and payment rates will go into effect on October 1, 2026. In the FY27 IPPS Final Rule, CMS addressed Carlsmed’s request and reassigned aprevo® Lumbar fusion procedures to three newly cre
- PRCarlsmed, Inc. To Participate in Upcoming Investor ConferencesCARLSBAD, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (NASDAQ:CARL) ("Carlsmed" or the "Company"), a medical technology company pioneering AI-enabled personalized spine surgery solutions today announced that management will participate in the following investor conferences: 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference. The Company will host one-on-one meetings on Monday, August 10, 2026.Bank of America SMID Cap Virtual Conference. Fireside chat on Wednesday, August 12, 2026, at 11:00 AM ET. A live webcast will be available to registered participants. Investors interested in participating in virtual one-on-one meetings should contact their Bank of America r
CARL FAQ
7 questionsWhat is the latest news on CARL?
In the last 30 days Quantisnow tracked 13 wire items for CARL: 5 insider trades, 3 SEC filings, 2 leadership changes and 2 press releases and news items. The most recent was published on October 27, 2026.Where does CARL stock trade?
Carlsmed Inc. (CARL) is listed on NASDAQ.What sector and industry is CARL in?
Carlsmed Inc. operates in the Health Care sector, Medical/Dental Instruments industry.When did Carlsmed Inc. go public?
Carlsmed Inc. (CARL) completed its IPO in 2025.What are analysts saying about CARL?
Carlsmed Inc. has had 6 recent analyst actions on file. The most recent action was from Needham: Buy with a $1700.00 price target on 2026-07-01. Recent price targets range from $1600.00 to $2100.00.What companies are similar to CARL?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), BDX (Becton Dickinson and Company), MDLN (Medline Inc.). Compare CARL side-by-side with any of them on Quantisnow.How can I track CARL on Quantisnow?
Quantisnow aggregates Carlsmed Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CARL to receive live email and push alerts on every new disclosure.